PARIS (AP) - Sanofi-Aventis has halted work on three experimental drugs including a once-promising depression treatment in order to focus its research and development efforts elsewhere, the European pharmaceutical giant said Wednesday.
Sanofi announced the decision to halt development of the three Phase III drugs followed a "comprehensive and rigorous" review of its R&D pipeline, which will also include axing several Phase II drugs and six projects that were in Phase I, Sanofi-Aventis said in a statement.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!